Immunoliposomes: A Multipurpose Strategy in Breast Cancer Targeted Therapy

Barrajón‐Catalán, Enrique; Menéndez-Gutierrez, María Piedad; Falcó, Alberto; Saceda, Miguel; Catania, Angela; Micol, Vicente

doi:10.5772/23998

Cited by 8 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this protocol the antibody must be derivatized in order to be linked to the lipid moieties. One of the most employed derivatization techniques, employed herein, uses the Traut’s reagent, which generates thiol groups in the antibody, allowing for the covalent bond through reaction with the maleimide in the DSPE-PEG-maleimide lipid [48, 49]. In the present work, the thiolated trastuzumab was successfully conjugated to DSPE-PEG-mal on the lipid bilayer surface via covalent bond.…”

Section: Resultsmentioning

confidence: 99%

Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells

Eloy¹,

Petrilli²,

Brueggemeier³

et al. 2017

ACAMC

View full text Add to dashboard Cite

Liposomes have been successfully employed in the clinic for several drugs to improve pharmacokinetics and reduce side effects. Furthermore, liposomes can be functionalized with antibodies for targeted delivery to cells that express the antigen. While the monoclonal antibody trastuzumab has been employed in the therapy of HER2-positive breast cancer, the resistance developed during treatment has been widely reported. Drugs, such as rapamycin, a lipophilic mTOR inhibitor, could be used in combination with trastuzumab for improved therapeutic response. In this study, we aimed to develop rapamycin-loaded liposomes and immunoliposomes with trastuzumab, characterize them and evaluate their in vitro cytotoxicity. Results showed that the SPC:Chol:DSPE-PEG formulation prepared at 1:10 drug to lipid ratio presented high encapsulation efficiency, appropriate particle size, low polydispersity, negative zeta potential and colloidal stability. Within the liposomes, rapamycin exhibited intermolecular interactions with lipids and underwent crystallinity reduction, indicated by FTIR and DSC. Rapamycin-loaded immunoliposomes were prepared with high trastuzumab functionalization efficiency, antibody stability and similar particle size, polydispersity and rapamycin encapsulation obtained with nontargeted liposomes. Cytotoxicity studies showed that the HER2-positive SK-BR-3 cell line was sensitive to trastuzumab, either as free drug or in the context of immunoliposomes, and is more sensitive to rapamycin than the triple negative MDA-MB-231 cells. For MDA-MB-231, the liposomal rapamycin was more cytotoxic than the free drug. Furthermore, the immunoliposomes showed potent cytotoxicity against SK-BR-3 cells. Finally, rapamycin and trastuzumab exhibited in vitro synergistic effect, particularly through immunoliposomes.

show abstract

Section: Resultsmentioning

confidence: 99%

Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells

Eloy¹,

Petrilli²,

Brueggemeier³

et al. 2017

ACAMC

View full text Add to dashboard Cite

show abstract

“…Multifunctional immuoliposomes have long circulation time and can carry more than one therapeutic and diagnostic agents (91). Immunoliposomes have successfully been targeted to tumor cells (92)(93)(94)(95), vascular endothelium (96) and infarcted heart tissue (97). Immunoliposome are meant to improve safety profile of potent drugs by limiting drug exposure to target sites but recently reported results of Shmeeda et al, (2013) found that liposomal zoledronic acid was almost 50 times more toxic than free zoledronic acid solution.…”

Section: Immunoliposomesmentioning

confidence: 99%

Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications

et al. 2014

View full text Add to dashboard Cite

-Liposomes are lipid based vesicular systems that offer novel platform for versatile drug delivery to target cell. Liposomes were first reported by Bangham and his co-workers in 1964 (1). Since then, liposomes have undergone extensive research with the prime aim to optimize encapsulation, stability, circulation time and target specific drug delivery. Manipulation of a liposome's lipid bilayer and surface decoration with selective ligands has transformed conventional liposomes into adaptable and multifunctional liposomes. Development of liposomes with target specificity provide the prospect of safe and effective therapy for challenging clinical applications. Bioresponsive liposomes offer the opportunity to release payload in response to tissue specific microenvironment. Incorporation of novel natural and synthetic materials has extended their application from stable formulations to controlled release targeted drug delivery systems. Integration and optimization of multiple features into one system revolutionized research in the field of cancer, gene therapy, immunotherapy and infectious diseases. After 50 years since the first publication, this review is aimed to highlight next generation of liposomes, their preparation methods and progress in clinical applications.

show abstract

“…Among tumor tissue, almost all the carcinomas carry EpCAM on their surface. They showed varying degrees of expression in cervix, lung, breast, prostate, renal cell, colon, rectum, and cutaneous squamous cell carcinoma [47,52,56,57]. The EpCAM expression is virtually absent in melanoma, primary central nervous system tumor, sarcoma, lymphoma, and germ cell tumors [44].…”

Section: Introductionmentioning

confidence: 95%

Systems for the delivery of chemotherapeutic drugs, new approaches and perspective

Jeewantha¹

2017

Russ Open Med J

View full text Add to dashboard Cite

Great perspectives in the field of drug therapy are currently associated with the targeted delivery of drugs to the organ, tissue or cells. Drug delivery systems (DDS) play a key role in enhancing the quality of chemotherapy in cancer disease. The intense interest in the topic of chemotherapy is the development of novel methods of drug delivery. The success of anti-tumor chemotherapy significantly dependends on the ability of therapeutic substances to achieve its target as well as minimal accumulation in non-specific sites (healthy organs and tissues). According to that, splendid perspectives in the field of chemotherapy are currently associated with the targeted delivery of drugs to the organs, tissues or cells. The essence of targeted delivery is that the drug itself, but more often a means of delivery systems (the vector, containers, and others.) modified by molecules, which can be identified by a unique receptor on cells or target sites. Then they are called "targeted drug delivery systems". At the same time, the engineering of multifunctional nanocarriers with several useful properties in one carrier (nanoparticles, liposomes, micelles, dendrimers, and others.) can significantly enhance the efficacy of many therapeutic and diagnostic protocols. In this article, summarize the accumulated information about potential possibilities of DDS, and the practical applications in cancer chemotherapy.

show abstract

Immunoliposomes: A Multipurpose Strategy in Breast Cancer Targeted Therapy

Cited by 8 publications

References 51 publications

Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells

Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells

Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications

Systems for the delivery of chemotherapeutic drugs, new approaches and perspective

Contact Info

Product

Resources

About